La cadena de opciones muestra datos clave de las opciones de acciones de OneConnect Financial Tech a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para OneConnect Financial Tech..

OneConnect Financial Tech (NYSE:OCFT) Bolsa, Cadena de Opciones

OneConnect Financial Tech

OneConnect Financial Technology Co Ltd is a technology-as-a-service provider for the financial services industry. It integrates extensive expertise in the industry with market technology to provide technology applications and technology-enabled business services to financial institutions. The integrated solutions and platforms it provides include digital banking solutions, digital insurance solutions, and the Gamma Platform, a technology infrastructure platform for financial institutions. Geographically, the company generates substantially all of its revenue from its business in the People's Republic of China (PRC).

OneConnect Financial Technology Co., Ltd. American Depositary Shares, each representing thirty ordinary shares

OneConnect Financial Technology Co Ltd

Uranium Energy (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UEC#AMEX">UEC</a>) reported quarterly losses of $(0.07) per share. This is a 40 percent decrease over losses of $(0.05) per share from the same period last year.

Earnings

News

Uranium Energy Q3 EPS $(0.07) Down From $(0.05) YoY

Barclays analyst Andrew Mok maintains Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) with a Overweight and lowers the price target from $522 to $480.

Price Target

Analyst Ratings

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $480

Rumors

Trading Ideas

Watching V.F. Corporation; Hearing Popular Newsletter Picks Stock

Piper Sandler analyst Allison Bratzel maintains Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) with a Overweight and raises the price target from $14 to $22.

REPL

Piper Sandler Maintains Overweight on Replimune Group, Raises Price Target to $22

<a href="https://www.nbcnews.com/politics/supreme-court/supreme-court-denies-challenges-state-laws-banning-assault-style-weapo-rcna187702">https://www.nbcnews.com/politics/supreme-court/supreme-court-denies-challenges-state-laws-banning-assault-style-weapo-rcna187702</a>
&nbsp;

SWBI

'Supreme Court Won't Hear Challenge To Maryland Assault Weapons Ban' - NBC News

Barclays analyst Andrew Mok maintains CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) with a Overweight and lowers the price target from $82 to $79.

Barclays Maintains Overweight on CVS Health, Lowers Price Target to $79

U.S. stocks traded lower this morning, with the Dow Jones index falling over 300 points on Monday.
Following the market opening Monday, the Dow traded down 0.72% to 41,967.43 while the NASDAQ fell 0.38% to 19,040.92. The S&amp;P 500 also fell, dropping, 0.58% to 5,877.58.
Check This Out: <a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a>
Leading and Lagging Sectors Energy shares jumped by 0.6% on Monday.
In trading on Monday, real estate stocks fell by 1.5%.
Top Headline
The Campbell&#8217;s Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) posted better-than-expected third-quarter results on Monday.
The company reported third-quarter sales growth of 4% year over year (Y/Y) to $2.475 billion, beating the analyst consensus estimate of $2.43 billion. Adjusted EPS of $0.73 beat the consensus estimate of $0.66.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>Lyra Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) shares shot up 486% to $28.90 after the company announced its ENLIGHTEN 2 Phase 3 trial of LYR-210 met its primary endpoint.</li>
<li>Shares of InMed Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INM#NASDAQ">INM</a>) got a boost, surging 194% to $7.31.</li>
<li>Oragenics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#NYSE">OGEN</a>) shares were also up, gaining 113% to $0.2455. Oragenics recently announced a 1-for-30 reverse stock split.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) shares dropped 31% to $5.64.</li>
<li>Shares of SharpLink Gaming, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBET#NASDAQ">SBET</a>) were down 34% to $50.45 after the company announced a mixed-shelf offering</li>
<li>Xilio Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) was down, falling 30% to $0.7457 after the company announced it commenced a public offering of pre-funded warrants.</li>
</ul>
Commodities In commodity news, oil traded up 3.1% to $62.67 while gold traded up 2.5% at $3,398.50.
Silver traded up 3.9% to $34.330 on Monday, while copper rose 4.5% to $4.8865.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.6%, while Spain's IBEX 35 Index fell 0.3%. London's FTSE 100 fell 0.3%, Germany's DAX 40 dipped 0.8% and France's CAC 40 fell 0.7% during the session.
Asia Pacific Markets
Asian markets closed lower on Monday, with Japan's Nikkei falling 1.30%, Hong Kong's Hang Seng Index dipping 0.57% and India's BSE Sensex declining 0.1%.
Economics
<ul class="wp-block-list">
<li>The ISM Manufacturing PMI declined to 48.5 in May compared to 48.7 in April, also missing market estimates of 49.5.</li>
<li>U.S. construction spending declined by 0.4% month-over-month to an annual rate of $2,152.4 billion in April following a revised 0.8% fall in March.</li>
<li>The S&amp;P Global manufacturing PMI was revised lower to a reading of 52 in May versus a preliminary reading of 52.3.</li>
</ul>
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/cannabis/25/06/45719355/top-3-utilities-stocks-that-may-crash-in-june">Top 3 Utilities Stocks That May Crash In June</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Commodities

Markets

LYRA

MULN

OGEN

SBET

Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings

Alliance Global Partners analyst Matthew Venezia initiates coverage on Pluri (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUR#NASDAQ">PLUR</a>) with a Buy rating and announces Price Target of $12.

Initiation

PLUR

Alliance Global Partners Initiates Coverage On Pluri with Buy Rating, Announces Price Target of $12

General

PATH

HCLTech and UiPath Announce Strategic Partnership To Drive Large-Scale Transformation For Enterprises Across Industries

Travelers Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRV#NYSE">TRV</a>) has outperformed the market over the past 5 years by 4.07% on an annualized basis producing an average annual return of 17.0%. Currently, Travelers Companies has a market capitalization of $61.76 billion. 
Buying $100 In TRV: If an investor had bought $100 of TRV stock 5 years ago, it would be worth $231.02 today based on a price of $272.60 for TRV at the time of writing.
<h3>Travelers Companies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748873713_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Travelers Companies 5 Years Ago Would Be Worth This Much Today

BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) and Bristol Myers Squibb &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) entered into a co-development and <a href="https://www.benzinga.com/pressreleases/25/06/b45717442/biontech-and-bristol-myers-squibb-announce-global-strategic-partnership-to-co-develop-and-co-comme" target="_blank" rel="noreferrer noopener">co-commercialization agreement</a>.
The pact focuses on BioNTech&#8217;s investigational bispecific antibody BNT327 across numerous <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">solid tumor types</a>.
Under the agreement, BioNTech and Bristol Myers Squibb will work jointly to broaden and accelerate the development of this clinical candidate.
Also Read: <a href="https://www.benzinga.com/25/05/45205736/biontech-appoints-novartis-executive-as-finance-chief-reaffirms-2025-guidance-focuses-on-oncology-expansion" target="_blank" rel="noreferrer noopener">BioNTech Appoints Novartis Executive As Finance Chief, Reaffirms 2025 Outlook Focusing on Oncology Expansion</a>
BioNTech&#8217;s BNT327 is currently under extensive evaluation in multiple ongoing clinical trials, with over 1,000 patients having received the treatment to date. 
These evaluations include global Phase 3 trials with registrational potential, investigating BNT327 as a first-line treatment for both extensive-stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC). 
Furthermore, BioNTech plans to initiate an additional global Phase 3 trial by the end of 2025 to assess the candidate&#8217;s efficacy in treating triple-negative breast cancer (TNBC).
Under the terms of the agreement, the companies will jointly develop and commercialize BNT327, including the development of BNT327 as monotherapy and in combination with other products. 
Both companies have the right to independently develop BNT327 in further indications and combinations, including combinations of BNT327 with proprietary pipeline assets.
Bristol Myers Squibb will pay BioNTech $1.5 billion in an upfront payment and $2 billion in non-contingent anniversary payments through 2028.
These tax-deductible charges will be recorded as Acquired IPR&amp;D Expense when incurred, with the $1.5 billion being incurred in Q2.
In addition, BioNTech will be eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones.
BioNTech and Bristol Myers Squibb will share joint development and manufacturing costs on a 50:50 basis, subject to certain exceptions. Global profits/losses will be equally shared between BioNTech and Bristol-Myers Squibb.
In May, Bristol-Myers Squibb agreed to pay $350 million to the State of Hawaii to settle claims related to the prescription drug Plavix, an antiplatelet drug that prevents blood clots by keeping platelets in the blood from coming&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45389547/bristol-myers-squibb-strikes-350-million-deal-to-end-hawaiis-plavix-lawsuit" rel="noreferrer noopener">together and making clots</a>.
The agreement resolves a lawsuit filed by the state that alleged the pharmaceutical company engaged in deceptive practices surrounding the development, labeling, and marketing of the drug.
Price Action: BNTX stock is trading higher by 14.8% to $109.95, and BMY stock is trading lower by 0.62% to $47.98 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asset-sales/25/06/45721138/dow-exits-dowaksa-jv-stays-course-on-best-owner-strategy" target="_blank" rel="noreferrer noopener">Dow Exits DowAksa JV, Stays Course On &#8216;Best-Owner&#8217; Strategy</a></li>
</ul>
Photo via Shutterstock

Biotech

Large Cap

Health Care

Movers

BNTX

Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug

U.S. stocks settled mixed on Friday, with the Dow Jones index gaining more than 50 points during the session after President Donald Trump accused China of "totally" breaching a tariff agreement, raising new fears over trade disputes.
Wall Street closed on a positive note last month, with the S&amp;P 500 gaining more than 6.2% in May and the Nasdaq jumping 9.6%. Both indices recorded their strongest months since November 2023. The Dow surged 3.9% for the month.
For the week, the S&amp;P 500 climbed, while the 30-stock Dow climbed 1.6%. The tech-laden Nasdaq, meanwhile, surged 2% last week.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Leo Mariani
<ul class="wp-block-list">
<li>Analyst Firm: Roth Capital</li>
<li>Ratings Accuracy: 88%</li>
<li>Latest Rating: Maintained a Buy rating on Sable Offshore Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOC#NYSE">SOC</a>) and cut the price target from $38 to $37 on May 27. This analyst sees around 22% upside in the stock.</li>
<li>Recent News: On May 21, Sable Offshore announced a $200 proposed public offering.</li>
</ul>
Analyst: Richard Davis
<ul class="wp-block-list">
<li>Analyst Firm: Canaccord Genuity</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Maintained a Hold rating on Okta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) and raised the price target from $100 to $115 on May 28. This analyst sees around 12% surge in the stock.</li>
<li>Recent News: On May 27, Okta reported first-quarter revenue of $688 million, beating analyst estimates of $680.25 million. The company reported adjusted earnings of 86 cents per share, beating analyst estimates of 77 cents per share.</li>
</ul>
Analyst: Trevor Walsh 
<ul class="wp-block-list">
<li>Analyst Firm: JMP Securities</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Market Outperform rating on Zscaler, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZS#NASDAQ">ZS</a>) and increased the price target from $240 to $310 on May 30. This analyst sees around 13% upside in the stock.</li>
<li>Recent News: On May 29, Zscaler reported third-quarter revenue of $678.03 million, beating the consensus estimate of $666.86 million.</li>
</ul>
Analyst: Jay McCanless
<ul class="wp-block-list">
<li>Analyst Firm: Wedbush</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Reiterated a Neutral rating on Cavco Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVCO#NASDAQ">CVCO</a>) with a price target of $550 on May 27. This analyst sees around 27% upside in the stock.</li>
<li>Recent News: On May 22, Cavco Industries posted upbeat quarterly results.</li>
</ul>
Analyst: William Stein
<ul class="wp-block-list">
<li>Analyst Firm: Truist Securities</li>
<li>Ratings Accuracy: 84%</li>
<li>Latest Rating: Maintained a Buy rating on NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and boosted the price target from $205 to $210 on May 29. This analyst sees around 56% upside in the stock.</li>
<li>Recent News: On May 28, Nvidia reported first-quarter revenue of $44.1 billion, up 69% year-over-year and up 12% from the fourth quarter. The revenue beat a Street consensus estimate of $43.2 billion.</li>
</ul>
Read More: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/large-cap/25/06/45719208/cramer-shouldve-told-investors-to-pull-the-trigger-on-trade-desk-cant-believe-how-low-gentex-has-fallen">Cramer: Should&#8217;ve Told Investors To &#8216;Pull The Trigger&#8217; On Trade Desk, Can&#8217;t Believe &#8216;How Low&#8217; Gentex Has Fallen</a> </li>
</ul>
Photo via Shutterstock

CVCO

NVDA

OKTA

5 Stock Picks Last Month From Wall Street's Most Accurate Analysts

U.S. SEC DECLARES FORM F-4 SEC REGISTRATION EFFECTIVE
SINGAPORE, June 2, 2025 /PRNewswire/ -- Hotel101 Global Holdings Corp. ("Hotel101" or "HBNB") and JVSPAC Acquisition Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JVSA#NASDAQ">JVSA</a>) ("JVSPAC") announced today that the United States Securities and Exchange Commission ("SEC") has declared effective Hotel101's registration statement on Form F-4 filed with the SEC in connection with the previously announced business combination agreement between Hotel101 and JVSPAC.
JVSPAC has scheduled the Extraordinary General Meeting of Shareholders ("EGM") on June 24, 2025 to vote on the proposed business combination with Hotel101.
The business combination values Hotel101 at an equity value of US$2.3 billion. The closing of the business combination is expected to occur as soon as possible, subject to regulatory and shareholder approvals and other customary closing conditions. Upon listing, the combined company will operate as Hotel101 Global Holdings Corp. and trade under the ticker symbol "HBNB". Once listed, Hotel101 will become the first Filipino-owned company to be listed and traded on Nasdaq. Hotel101 is a subsidiary of Philippine-listed DoubleDragon Corporation (PSE: DD).

JVSA

U.S. SEC Declares Hotel101's Form F-4 Registration Effective As JVSPAC Sets June 24 Shareholder Meeting To Vote On Proposed Business Combination; Upon Listing, The Combined Co Will Operate As Hotel101 Global Holdings Corp. And Trade Under The Ticker Symbol "HBNB"

WIIM

Tempus AI shares are trading higher after the company introduced its fuses program for precision-based medicine and xM for advanced cancer treatment response monitoring.

Barclays analyst Andrew Mok maintains Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>) with a Overweight and raises the price target from $382 to $385.

Barclays Maintains Overweight on Cigna Group, Raises Price Target to $385

<a href="https://www.bloomberg.com/news/articles/2025-06-02/trump-wants-to-sell-us-s-1-million-barrel-reserve-of-diesel-fuel?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-06-02/trump-wants-to-sell-us-s-1-million-barrel-reserve-of-diesel-fuel?embedded-checkout=true</a>

'Trump Wants to Sell US's 1 Million Barrel Reserve of Diesel Fuel'- Bloomberg

Barclays analyst Adrienne Yih maintains Ulta Beauty (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) with a Equal-Weight and raises the price target from $327 to $485.

ULTA

Barclays Maintains Equal-Weight on Ulta Beauty, Raises Price Target to $485

BTIG analyst David Larsen upgrades Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) from Neutral to Buy and maintains the price target from $80 to $80.

Upgrades

DOCS

BTIG Upgrades Doximity to Buy, Maintains Price Target to $80

Barclays analyst David Strauss maintains Heico (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HEI#NYSE">HEI</a>) with a Equal-Weight and raises the price target from $250 to $280.

Comments

OneConnect Financial Tech

OneConnect Financial Tech (OCFT) Opciones

OneConnect Financial Tech (NYSE:OCFT) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL